Biophytis (BPTSY) has released an update.
Biophytis, a biotech firm targeting age-related diseases, has filed an IND application with the FDA for a phase 2 obesity study of its drug BIO101. The international multicenter study, set to begin in mid-2024, aims to improve muscle strength in obese patients using BIO101 in combination with a hypocaloric diet and GLP-1 RAs. Anticipated to address a potential $100 billion market by 2030, Biophytis’s CEO highlights the strategic importance of this study for the company’s growth and potential partnerships.
For further insights into BPTSY stock, check out TipRanks’ Stock Analysis page.
